Ambry Genetics News and Activities

Ambry Genetics is owned by Konica Minolta.

Konica Minolta is one of the...

• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Konica Minolta is a company listed under the stock ticker 4902 (JP).

Konica Minolta has a direct presence in 11 countries.

Konica Minolta has 15 subsidiaries including Ambry Genetics, Konica Minolta Australia and Konica Minolta Business Solutions Asia.

They are in:

• Office Equipment63%
• Biotechnology19%
• Other19%

View the org chart displaying its 13 main executives

Most searched biographies at Ambry Genetics

• Tom Schoenherr, Chief Executive Officer
• Samuel Giardina, Regional Vice President, West
• Michelle Smith, General Counsel

Popular executive movements at Ambry Genetics

• Mickie Henshall, Chief Marketing Officer, has left the company  (posted on April 30 2026).

Create your alert
to follow the executive moves at Ambry Genetics.

Konica Minolta has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Ambry Genetics

• Genetics in Medicine Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing 
• Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”
• Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes
• Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield 
• Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity  
• Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
• Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
• New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis
• Ambry Genetics Data Supports Functional Study of BRCA2 Helping Improve Variant Classification for Hereditary BRCA2-Linked Cancers 
• Ambry Genetics Expands Its Award Collection with Three New Comparably Best Place to Work Honors for 2024
• View more press releases Close

Social media about Ambry Genetics

• Ambry Genetics on Wikipedia, Google News & Yahoo Finance
• Ambry Genetics on LinkedIn, X (Twitter) & YouTube